Efficient methods for producing antimicrobial cationic peptides in host cells

a cationic peptide, host cell technology, applied in the direction of peptides, peptide sources, applications, etc., can solve the problems of low cost, loss of potassium ions, and decrease of cytoplasmic atp, and achieve the effect of mass-production methods, low cost, and low cos

Inactive Publication Date: 2005-11-24
COMPHARE TRUST COMPANY
View PDF12 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to their amphipathic nature, the peptides disrupt the membrane, causing a loss of potassium ions, membrane depolarization, and a decrease in cytoplasmic ATP.
A practical drawback in cationic peptide therapy is the lack of a cost effective, mass-production method of the agents.
Typically, the isolation of cationic peptides from natural sources is not cost-effective, and does not apply to the production of engineered cationic peptide variants which may have increased efficacy.
While chemical peptide synthesis can be used to manufacture either natural or engineered cationic peptides, this approach is very costly.
Nevertheless, recombinant gene expression from a host cell presents a number of technical problems, particularly if it is desired to produce large quantities of a particular protein.
For example, if the protein is a cationic peptide, such peptides are very susceptible to proteolytic degradation, possibly due to their small size or lack of highly ordered tertiary structure.
Yet there is no general way to predict which protease-deficient strains will be effective for a particular recombinant protein.
However, any sequence that interferes with bacterial growth through replication or production of products toxic to the bacteria, such as lytic cationic peptides, are problematic for cloning.
The approach outlined above suffers from the inherent limitation on overall productivity imposed by the use of a small single peptide (circa 10%) in the large fusion protein.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Efficient methods for producing antimicrobial cationic peptides in host cells
  • Efficient methods for producing antimicrobial cationic peptides in host cells
  • Efficient methods for producing antimicrobial cationic peptides in host cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction of Plasmids PET21CBD-X(B) AND PET21CBD96

[0104] Plasmid vector pET21a(+) (Novagen Corporation, USA), a T7 expression plasmid, was used as the core plasmid for all expression systems (FIGS. 1A and 10). The cellulose binding domain (CBD) from Clostridium cellulovorans was selected as a carrier protein for expression of antibacterial cationic peptides. Plasmid pET-CBD180 (Shpigel et al., supra) was used as the starting material (FIGS. 1B and 10). Restriction enzymes except VspI and NsiI (Promega Corporation, USA), T4 DNA ligase and Taq polymerase were purchased from Pharmacia Biotech. The relevant part of CBD, including the T7 promoter of pET-CBD180, was amplified by PCR using 25 pmol each of each of the primers GCGT CCGG CGTA GAGG ATCG (SEQ ID NO:1) and CCGG GATC CAAT GTTG CAGA AGT AG (SEQ ID NO:2), 2 U of Taq DNA polymerase, corresponding reaction buffer (10× PCR reaction buffer: 500 mM KCl, 15 mM MgCl2, 100 mM Tris-HCl, pH 9), 0.2 mM dNTPs (dATP, dGTP, dTTP and dCTP, Ph...

example 2

Construction and Expression of CBD—MBI-11 Fusions

[0106] Sequences encoding all cationic peptides were designed from modified indolicidin, a natural anti-microbial peptide. Plasmids pET21CBD-X and pET21CBD96 (0.25 μg each) were digested with 2 U of BamHI and 2 U of HindIII in 1.5× OPA in 50 μl reactions at 37° C. for 1 hour. In the same way, a fragment encoding MBI-11 was digested (Example 4) using about 1 μg of DNA and 25U of BamHI and HindIII each in a 100 μL reaction. Both reactions were stopped by phenol / CHCl3 (Sigma-Aldrich Canada Ltd.) extraction and ethanol precipitation. The resultant DNAs of each vector and MBI-11 insert were dissolved in 8 μl of water and mixed, then 2 μl of 10 mM ATP, 2 μl of 10× OPA and 2 U of T4 DNA ligase were added and ligation reactions were incubated at 10° C. for 1 hour. Then 2 μl of each ligation mixture was used to electroporate 40 μl of E. coli XL1 Blue using sterile Gene Pulser cuvettes (0.2 cm electrode gap) and Gene Pulser electroporator appa...

example 3

Expression of CBD Fused Polycationic Peptide Tandem Domains

[0107] This experiment was designed to test how many peptide genes in tandem can be fused to a carrier protein and expressed. It was necessary to create two DNA fragments encoding MBI-11, one for polymerization by DNA cloning and another one as the last gene in the tandem. Therefore, the original DNA fragment encoding MBI-11 peptide with COOH end was modified in order to create the last gene in tandem (Example 4) and a new gene was designed for a specific cloning procedure, which allowed construction of multiple tandem peptide genes fused to CBD180 or CBD96 carrier proteins genes (Example 4). The cloning procedure resulted in addition of an extra isoleucine to the MBI-11 tandem sequences. Therefore in order to produce identical peptide molecules, an isoleucine codon was also added to the last gene sequence. CNBr will be used to cleave the peptide from fusion proteins, which means that peptide molecules would have a homoseri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
flow rateaaaaaaaaaa
temperatureaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of allowed U.S. patent application Ser. No. 09 / 444,281, filed Nov. 19, 1999, which application claims priority from U.S. Provisional Application Ser. No. 60 / 109,218, filed Nov. 20, 1998; and each of these applications is incorporated by reference in its entirety.TECHNICAL FIELD [0002] The present invention relates generally to methods for obtaining recombinant peptides and proteins from host cells. In particular, the present invention relates to improved processes for producing and purifying cationic peptides from recombinant host cells in which the peptide is expressed in high yield and is easily recovered. BACKGROUND OF THE INVENTION [0003] Antimicrobial peptides, particularly cationic peptides have received increasing attention as a new pharmaceutical substance, because of their broad spectrum of antimicrobial activities and the rapid development of multi-drug-resistant pathogenic microorganisms. En...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07H21/04C07K1/00C07K14/47C12N1/21C12N15/62C12N15/63C12P21/04C12P21/06
CPCC07K14/4723C12N15/62C07K2319/50
Inventor BURIAN, JANBARTFELD, DANIEL
Owner COMPHARE TRUST COMPANY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap